Key result
A 45-year-old female with lung metastases from breast cancer developed a right pneumothorax due to a bronchopleural fistula caused by rapid tumor necrosis following Bevacizumab and paclitaxel therapy.
Why the study?
Bevacizumab combination therapy is associated with adverse events including pneumothorax, but the underlying molecular mechanisms are not fully understood.
Case Report (n=1)
Patients with lung metastases surrounding the bronchi and on the pleura should be monitored for pneumothorax when receiving Bevacizumab-containing chemotherapies.
Pneumothorax risk warrants vigilance during bevacizumab in lung metastases; extends case literature but leaves open prospective validation.
BACKGROUND: Bevacizumab is an antiangiogenic agent, and that synergizes with chemotherapeutic drugs. When used in combination therapies, Bevacizumab is associated with adverse events such as hemorrhage, gastrointestinal perforation, delayed wound healing, and pneumothorax. However, the molecular mechanisms underlying these adverse events are not fully understood. CASE SUMMARY: day of drainage, the patient was discharged from our hospital on recovery. Recurrence of pneumothorax was not reported, and continuation of chemotherapy was made possible by changing the regimen. CONCLUSION: Patients with lung metastases surrounding the bronchi and on the pleura should be monitored for pneumothorax by Bevacizumab-containing chemotherapies.
No takes yet. Share an insight, caveat, or question.
Ozaki et al. (2020) conducted a case report in Breast cancer with multiple lung metastases (n=1). Bevacizumab and paclitaxel was evaluated on Development of pneumothorax. A 45-year-old female with lung metastases from breast cancer developed a right pneumothorax due to a bronchopleural fistula caused by rapid tumor necrosis following Bevacizumab and paclitaxel therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: